survival in patients with HCC (12) , suggesting that this class of agents may be effective in the treatment of HCC.
Brivanib is hydrolyzed to the active moiety BMS-540215 in vivo. BMS-540215 shows potent and selective inhibition of VEGFR and fibroblast growth factor receptor (FGFR) tyrosine kinases (13) . The structures of brivanib and BMS-540215 are shown in Fig. 1 . BMS-540215 is an ATP-competitive inhibitor of human VEGFR-2, with an IC 50 of 25 nmol/L and K i of 26 nmol/L. In addition, it inhibits VEGFR-1 (IC 50 = 380 nmol/L) and VEGFR-3 (IC 50 = 10 nmol/L). BMS-540215 also showed good selectivity for FGFR-1 (IC 50 = 148 nmol/L), FGFR-2 (IC 50 = 125 nmol/L), and FGFR-3 (IC 50 = 68 nmol/L). Furthermore, BMS-540215 has been shown to selectively inhibit the proliferation of endothelial cells stimulated by VEGF and FGF in vitro with IC 50 values of 40 and 276 nmol/L, respectively (13) . It also shows broad-spectrum in vivo antitumor activity over multiple dose levels and induces stasis in large tumors, suggesting that it may have a role in the treatment of HCC.
High expression of angiogenic factors VEGF, basic FGF (bFGF), and insulin-like growth factor (IGF)-2 is detected in 2 patients with HCC (14 -17) , and when released from tumor cells, inflammatory cells, and/or tumor stromal cells, they participate in the neovascularization and metastatic potential of HCC (18 -20) . VEGF is considered one of the most important of all of the angiogenic factors involved in HCC vascularization. Plasma VEGF levels are significantly elevated in patients with HCC and distant metastasis (21) , and the increased expression of VEGF is correlated with histologic tumor grade (22) and tumor microvessel density (23) . In addition, high preoperative serum levels of VEGF are predictive of microscopic venous invasion (24) and poor response to chemoembolization (25) . bFGF or FGF-2 is also a potent angiogenic factor in HCC (14, 26, 27) . bFGF stimulates the release and activity of collagenases, proteases, and integrins on the extracellular membrane to form nascent microvascular networks (28) . The expression of heparanase in connection with bFGF enhances growth, invasion, and angiogenesis of the tumor (29) . Indeed, in a clinical study of patients undergoing resection of HCC, a high preoperative serum bFGF level seemed to be predictive of invasive tumor and early postoperative recurrence (30) . Furthermore, bFGF has been shown to synergistically augment VEGF-mediated HCC development and angiogenesis (31) . It functions as a mitogen for HCC cell proliferation via an autocrine mechanism and enhances the development and progression of HCC by binding to FGFR-1 (32) . Because VEGFRs and FGFRs are both present on endothelial cells and provide critical signaling pathways for HCC metastasis, the use of brivanib that inhibits both VEGFR and FGFR could be of therapeutic importance.
Here, we report the results of a study assessing the effects of brivanib, a dual VEGFR and FGFR inhibitor, on tumor growth and apoptosis in mouse models of human HCC, which have previously been established and characterized to investigate novel compounds for the treatment of HCC (33) .
Materials and Methods
Reagents. Research-grade Capsitol was purchased from CyDex, Inc. Primary antibodies against CD31/platelet endothelial cell adhesion molecule 1, p130 RB, p21 WAF1 , p27 Kip1 , and Ki-67 were from Lab Vision. Anti-Akt (Ser ) antibodies were from Epitomics, Inc. Antibodies against FGFR-1, FGFR-2, FGFR-3, FGFR-4, pRB, cyclin D1, cyclin-dependent kinase (Cdk)-2, Cdk-4, cdc-2, cyclin A, cyclin B1, Bax, Bad, Bcl-2, Bcl-x, and a-tubulin were from Santa Cruz Biotechnology, Inc. Recombinant VEGF, platelet-derived growth factor-AB, and IGF-I were purchased from Millipore Corp. Conjugated secondary antibodies were supplied by Pierce. The chemiluminescent detection system was supplied by Amersham Pharmacia Biotech. Tris-base, NaCl, EDTA, EGTA, Triton X-100, sodium pyrophosphate, h-glycerolphosphate, Na 3 VO 4 , leupeptin, and phenylmethylsulfonyl fluoride were obtained from Sigma Chemical Co.
Cell culture. SK-HEP1 and HepG2 cells were obtained from the American Type Culture Collection. They were maintained in modified Eagle's medium (Life Technologies) supplemented with 10% fetal bovine serum (growth medium). SK-HEP1 cells were selected for in vitro studies because they are of endothelial origin cells that express both VEGFR-2 and FGFR-1 (34) . To study the effects of brivanib treatment on VEGF-and bFGF-stimulated activation of Akt and ERK1/2 pathways, SK-HEP1 and HepG2 cells were treated with 2 Amol/L brivanib for 24 h and then stimulated with 40 ng/mL VEGF or bFGF. In addition, brivanib SK-HEP1 cells were also stimulated with IGF-1 for 15 min. The cells were lysed and the lysates were analyzed for levels of the effector proteins, including the serine/threonine kinase Akt and ERK1/2.
Xenograft models. This study received ethics board approval at the National Cancer Centre of Singapore and Singapore General Hospital. All mice were maintained according to the Guide for the Care and Use of Laboratory Animals published by the NIH. They were provided with sterilized food and water ad libitum and housed in negative pressure isolators with 12-h light/dark cycles.
Previously Tumor treatment. Brivanib (Bristol-Myers Squibb, Pharmaceutical Research Institute) was diluted in vehicle (30% Capsitol in water) at an appropriate concentration. To investigate the effects of brivanib on the growth of patient-derived HCC xenografts, mice bearing the tumors described above were orally given 50 or 100 mg/kg brivanib daily or 200 AL vehicle for 12 d. For the dose-response experiments, mice bearing the xenograft line 06-0606 were given two doses of brivanib (50 and 100 mg/kg daily) orally starting on day 7 after tumor implantation. Each treatment group comprised 14 animals and each experiment was repeated at least thrice. Treatment started on day 7 after tumor implantation, by which time the patient-derived HCC xenografts were f100 mm 3 in size. Tumor growth was monitored at least twice weekly by vernier caliper measurement of the length and width of tumor. The tumor volume was calculated as follows: length Â width 2 Â p/6. At the end of the study, the mice were sacrificed with body and tumor weights being recorded, and the tumors were harvested for analysis.
The efficacy of brivanib in reducing tumor growth was analyzed by the treatment to control (T/C) ratio, where T and C are the median weight (mg) of brivanib-treated and vehicle-treated tumors, respectively, on treatment day 12. T/C ratios V0.42 are considered an active response according to the Drug Evaluation Branch of the Division of Cancer Treatment, National Cancer Institute criteria.
Western blot analysis. To determine changes in proteins [cleaved caspase-3, cleaved PARP, anti -VEGFR-2, anti -phospho-VEGFR-2 (Tyr   1054/1059 ), phospho-c-Myc (Tyr 58 /Ser 62 ), FGFR-1, FGFR-2, FGFR-3, FGFR-4, pRB, cyclin D1, Cdk-2, Cdk-4, cdc-2, cyclin A, cyclin B1, Bax, Bad, Bcl-2, Bcl-x, and a-tubulin], independent tumors from mice treated with vehicle (n = 3) and brivanib (n = 3-4) were homogenized in buffer containing 20 mmol Tris (pH 7.5), 150 mmol NaCl, 1 mmol/L EDTA, 1 mmol EGTA, 1% Triton X-100, 2.5 mmol sodium pyrophosphate, 1 mmol h-glycerolphosphate, 2 mmol Na 3 VO 4 , 1 Ag/mL leupeptin, and 1 mmol phenylmethylsulfonyl fluoride (33) . The protein concentration was determined by Bio-Rad protein assay (Bio-Rad Laboratories). Western blot analysis of samples (100 Ag protein per sample) to analyze the effect of brivanib treatment on markers of apoptosis and cell cycle regulation was undertaken according to standard protocols (35) . Blots were incubated with indicated primary antibodies and 1:7,500 horseradish peroxidase -conjugated secondary antibodies. All primary antibodies were used at a final concentration of 1 Ag/mL. The blots were then visualized with a chemiluminescent detection system.
Immunohistochemistry. Tumor tissue samples were processed for paraffin embedding and 5-Am sections were prepared. After blocking Research.
on July 14, 2017. © 2008 American Association for Cancer clincancerres.aacrjournals.org Downloaded from endogenous peroxidase activity and nonspecific staining, the sections were incubated overnight at 4jC with the primary antibodies against CD31, Ki-67, and cleaved caspase-3 used to assess microvessel density, cell proliferation, and apoptosis, respectively.
Immunohistochemistry was done using the streptavidin-biotin peroxidase complex method according to the manufacturer's instructions (Lab Vision). For Ki-67, only the nuclear immunoreactivity was considered positive. The number of Ki-67 -positive cells among at least 500 cells per region was counted and expressed as percentage values. For the quantification of mean microvessel density in sections stained for CD31, 10 random 0.159-mm 2 fields at Â100 magnification were captured for each tumor.
Statistical analysis. The differences in tumor growth among the treatment groups, body weight, tumor weight at sacrifice, mean microvessel density, percentage of Ki-67 -positive cells, and cleaved caspase-3 -positive cells were compared using ANOVA. Experiments were repeated at least thrice.
Results
As shown in Fig. 2A , the growth rate of tumors in mice with patient-derived xenograft line 06-0606 was decreased by brivanib treatment in a dose-dependent manner (P < 0.01). Tumor weights in these mice that were treated with 50 and 100 mg/kg brivanib by gavage daily for 12 days were approximately 55% and 13%, respectively, compared with vehicle-treated mice. Furthermore, brivanib, at a dose of 100 mg/kg, also inhibited tumor growth in mice with patientderived xenograft lines 2-1318 (Fig. 2B ) and 26-1004 (P < 0.01; Fig. 2C ). Maximal inhibition was seen at 100 mg/kg in all patient-derived xenograft lines ( Table 1 ). The T/C ratios for xenograft lines 2-1318, 5-1318, 26-1004, 2006 , and 06-0606 were 0.38, 0.40, 0.34, 0.60, 0.38, and 0.13, respectively, after 12 days of treatment. Furthermore, growth suppression was seen in 06-0606, 2-1318, and 26-1004 xenograft lines 7 days after treatment (Fig. 2) . As the 100 mg/kg daily dose gave maximal growth inhibition, this dose was used for all subsequent studies. Brivanib also inhibited the growth of the 26-1004 xenograft line in an orthotopic model ( Supplementary Fig. S1 ). No overt toxicity, as defined by weight loss (Fig. 2D) , unkempt appearance, mortality, and behavior, was observed in either brivanib treated or vehicletreated mice during the course of treatment (data not shown).
No significant difference in VEGFR-2 levels was observed among six xenograft lines studied (Fig. 3) . Variable levels of each FGFR were detected with the exception of the xenograft line 06-0606, which expressed all four FGFRs. Interestingly, this (Fig. 3) .
The treatment with brivanib led to significantly decreased mean blood microvessel density, which is consistent with inhibition of angiogenesis, in all patient-derived xenografts tested with the greatest decrease in the xenograft line 06-0606 (P < 0.01; Fig. 4) . Furthermore, the median number of CD31-positive endothelial cells in brivanib-treated mice was significantly reduced in all six patient-derived xenograft lines compared with control (P < 0.01; Table 1 ).
Immunohistochemical analysis revealed that the Ki-67 labeling index was significantly decreased in all six brivanibtreated xenograft lines compared with control (P < 0.01; Table 1 ). The percentage of cells stained for cleaved caspase-3 was significantly increased in brivanib-treated tumors (P < 0.01; Fig. 4 ; Table 1 ), suggesting that brivanib caused apoptosis of HCC cells. Again, the greatest changes in Ki-67 labeling and cleaved caspase-3 staining were in the xenograft line 06-0606.
The activation status of VEGFR-2 was investigated in xenograft lines 06-0606 and 26-1004 after 12 days of treatment with brivanib or control. Although there was no significant increase in VEGFR-2 expression, the levels of phosphorylated VEGFR-2 at Tyr 1054/1059 , Akt at Ser 473 , and ERK1/2 at Thr 202 /Tyr 204 in the brivanib-treated tumors were significantly decreased (P < 0.01), suggesting that the VEGFR-2 was inactivated (Fig. 5) . No significant changes in FGFR-1 protein expression levels were observed in both xenograft lines 06-0606 and 26-1004 (Fig. 5) . Brivanib induced significant reductions in the levels of Cdk-4, cyclin B1, and phospho-c-Myc (P < 0.01; Fig. 5 ). Moreover, brivanib also significantly increased the levels of cleaved caspase-3 and cleaved PARP without altering the levels of Bcl-x, Bcl-2, Bad, and Bax (P < 0.01; Fig. 5 ), indicating that brivanib may induce apoptosis by Bcl-2 -independent mechanisms. There were no significant alterations in the levels of Cdk-6, E2F1, pRB, p130 RB, p27
Kip1 , p21 WAF1 , and cyclin A in brivanib-treated mice (data not shown).
To address the mechanism by which brivanib inhibits tumor growth, we evaluated the effect of brivanib on the phosphorylation levels of VEGFR-2 and FGFR-1, and their downstream signaling pathways, ERK1/2 and Akt, in SK-HEP1 cells and HepG-2 cells. In nonstimulated SK-HEP1 cells, brivanib alone had little effect on levels of phosphorylated ERK1/2, Akt, VEGFR-2, and FGFR-1. However, in VEGF-and bFGF-stimulated cells, brivanib significantly inhibited VEGFR-2, FGFR-1, ERK1/ 2, and Akt phosphorylation (Fig. 6A) . In contrast, brivanib had no effects on IGF-1 -induced ERK1/2 and Akt phosphorylation (Fig. 6B) . Total VEGFR-2, FGFR-1, ERK1/2, and Akt levels were unchanged.
Discussion
This study showed that brivanib effectively inhibits tumor growth in five of six patient-derived human HCC xenograft lines. Furthermore, brivanib-induced growth inhibition was associated with inactivation of VEGFR-2, increased apoptosis, a reduction in microvessel density, inhibition of cell proliferation, and down-regulation of cell cycle regulators, including cyclin D1, Cdk-2, Cdk-4, cyclin B1, and phospho-c-Myc. Indeed, cell cycle arrest due to a reduction in positive cell cycle regulators may be responsible for the observed growth inhibition. It has previously been shown that conditional expression of the c-Myc oncogene in mouse liver results in the development of HCC (36) . Treatment with brivanib also led to a decrease in the number of proliferating cells compared with control. The exact mechanisms by which brivanib treatment induces growth inhibition are not well understood. A previous study (13) has shown that brivanib affected the host endothelium based on both in vitro and in vivo studies (vascular density, Matrigel plugs, and dynamic Research.
on July 14, 2017. © 2008 American Association for Cancer clincancerres.aacrjournals.org Downloaded from contrast-enhanced magnetic resonance imaging responses). It had no antiproliferative effects on L2987 lung carcinoma, HCT116 colon carcinoma, H3396 breast carcinoma, and CWR-22 prostate carcinoma cell lines in culture. Our present study shows that brivanib also acts in vitro on endothelial cells (Fig. 6A ) and HepG2 cells (Fig. 6C ) when stimulated with VEGF or FGF (Fig. 6A) , suggesting that depending on the cell types studied brivanib may also have direct tumor activity in vivo. Brivanib may prevent the tumor mass from expanding by cutting off the supply of nutrients and growth factors to the tumor cells. In addition, the percentage of cells stained with cleaved caspase-3 was significantly increased in brivanibtreated tumors compared with control, suggesting that brivanib caused apoptosis of HCC cells.
It was shown that the six patient-derived HCC xenograft lines expressed all four FGFRs to varying levels; levels of FGFR-1 expression were lower in xenograft line 30-1004 compared with the other five xenograft lines, which correlates well with its sensitivity to brivanib. In addition, the xenograft line 06-0606, which expresses high levels of all four FGFRs, was particularly sensitive to brivanib, suggesting that the expression of FGFR-2, FGFR-3, and FGFR-4 may also contribute to its response toward brivanib. In this study, multiple forms of FGFR-2 were detected in xenograft lines 06-0606, 2006, and 30-1004. The exact role of FGFR-2 and its variants in HCC growth and angiogenesis remains to be elucidated. However, it should be noted that the xenograft line 06-0606 expressed very high levels of FGFR-2. It has been reported that somatic missense mutations of FGFR-2 are implicated in tumorigenesis, which has also been shown in cell lines of multiple tumor types and primary tumors (37, 38) . Further studies are under way to investigate the role of FGFR-2 and its variants in angiogenesis and the development and progression of HCC. Additional evidence for the tumor growth-inhibitory effects of brivanib being due to its effects on VEGFR-2 and FGFR-1 was shown in SK-HEP1 cells, hepatocellular adenocarcinoma cells of endothelial origin.
Targeted inhibition of angiogenesis and induction of apoptosis using a dual inhibitor of VEGFR and FGFR tyrosine kinases may represent a good alternative treatment to currently available options for patients with HCC. Most patients present clinically with late-stage HCC with some individuals already having widespread tumor dissemination. Patients who have undergone liver transplantation, resection, or liver-directed therapy have the greatest likelihood of developing primary or recurrent HCC. Therefore, the potent antiangiogenic activity of brivanib makes this drug potentially useful in maintaining dormancy of micrometastasis and preventing the development of recurrence or metastasis after surgical resection of a primary tumor. Furthermore, brivanib showed direct growth inhibition and induction of apoptosis. These effects may be mediated through FGF because FGFRs are present on endothelial cells and represent a critical signaling pathway for tumors. Although several new chemotherapies have been explored and refined in the last decade, the mortality rate due to HCC remains unchanged. New therapeutic strategies for HCC treatment are urgently needed. The important roles of the VEGF and FGF signaling pathways in promoting tumor angiogenesis and metastasis, together with its negative prognostic significance in HCC, make them appropriate therapeutic targets.
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